Personalized diagnosis and therapy of cancer in our knowledge society and UN,WHO,UNHCR-Dr.Nabil DEEB

فلسطينيو العراق3

عدد القراء 2281

http://www.paliraq.com/images/paliraq-english/paliraq01.JPG
 
http://www.paliraq.com/images/paliraq2012/hos.bmp
 

Personalized diagnosis and therapy of cancer in our knowledge society
and the UN, WHO and UNHCR - Dr. Nabil DEEB

We are doctors and medical researchers worldwide are working and researching medical science with advanced technology methods for the diagnosis and treatment of numerous diseases .

Unfortunately, we find that many war-damaged cancer patients Palestinian children can not and will not be treated .

I would add, personalized diagnosis and therapy of cancer in our knowledge society .

Personalized cancer therapy in the knowledge society : -

The proteome is the set of proteins that are found in a biological system at any given time. In a single cell can have more than 100,000 different proteins exist in very different quantities. While the genome, so the meaning specified in the DNA genetic information for life remains the same, the proteome is again the current state of a biological system. On this rests the hope of proteomics to improve the search for changes in protein composition, for example, before and after administration of a drug, the chances of medical treatment. Biomarkers are molecules of certain characteristic patterns that indicate specific biological processes. They can provide information as to whether a patient responds to treatment .

Molecular causes of cancer. Random mutations in any cell in the body lead to increased growth signals, repair or protective systems are turned off. Only when meet more of these genetic changes unfavorably, causes cancer. Since there are many possible combinations of immense, which can lead to a similar result, every tumor is unique. In addition, the inherited genetic basic configuration of the patient also plays a role. It therefore seems logical to first analyze molecular cancers to treat it and then individually .

In personalized medicine knowledge from molecular biology, diagnostics and therapy are combined. This so-called biomarkers are identified by groups of patients who respond to a particular therapy, where she remains without success, or are likely to have severe side effects. As examples of the personalized medicine new treatments for cancer, AIDS, and were called rheumatism .

Basically, the search for biomarkers discovered recently by the use of so-called high-throughput substantially. Depending on the molecular targets may be the search for disease-specific biomarkers in molecular weight following levels:

• the genome (search for genetic polymorphisms, SNPs) .

• the transcriptome (the totality of all at some point in a cell or tissue produced messenger RNA molecules) .

• the proteome (the totality of all at some point in a cell or tissue synthesized proteins) .

Even if you are identified by this strategy potentially single molecules as biomarkers so, experience shows that are just for multifactorial diseases such as rheumatoid arthritis or cancer only certain patterns of several pathological molecules capable of clinically similar diseases at the molecular level . differ Therefore, we also speak of so-called biomarker profiling .

Damage to the DNA sequence of cause for new knowledge, only about half of all cancers. Understood and much worse - - Just as important are the epigenetic causes of cancer in which the control of the genetic material is permanently disrupted .

Chromosomes consist of DNA in addition to about fifty percent from proteins. These proteins are DNA-packaging materials, specifically control the activation and deactivation of genes and allow them to take the approximately 100 trillion cells of humans, their specific forms and functions, although these cells contain one and the same DNA sequence .

Like most complex systems is also the regulation of gene activity by the protein packaging of DNA prone to error. Although most damage will be repaired successfully, but sometimes gets the gene regulation of a cell finally turned out of control and the cell into a cancer cell. Such changes in the genome are equally important for the development of cancer, such as the well-known DNA mutations, although the DNA sequence itself is not damaged thereby. For distinguishing one speaks of epigenetic modifications, in contrast to genetic alterations, in which the DNA sequence is changed .

The fundamental achievements of modern genome research, technological advances in the field of molecular biology and biochemistry, improved diagnostic methods and new technologies enable the development of drugs against cancer cells, the development of customized and personalized cancer treatment. The decisive factor is the discovery of molecular 'switching errors' in cancer cells that can be detected by appropriate diagnostic procedures and corrected by drugs with molecularly targeted effect .

Large international studies have confirmed the success of personalized therapy approaches in cancer therapy. Were able to increase significantly with customized, personalized cancer therapy, the therapeutic response and survival of cancer patients in patients with lymphoma, myeloma, breast, prostate or colon cancer in recent years. These successes have been led to broad application of this novel cancer therapeutics .

The Cancer Epigenetics deals with molecular changes that lead to a permanent disorder of gene regulation in the same DNA sequence intact. In particular, these are changes in the proteins that package the DNA and organize. From a better understanding of these mechanisms is hoped that new opportunities for cancer screening, cancer diagnosis and treatment of cancer .

The development of molecularly targeted cancer therapeutics safe opened many cancer patients the chance of a better effective treatments with fewer side effects compared to conventional chemotherapy and better survival. These modern cancer drugs are immune substances (antibodies) . The use of these drugs is in accordance with specific biological characteristics of cancer and usually requires a costly cancer diagnosis and a lot of experience on the part of treating cancer specialists in dealing with these drugs .

Personalized therapy for non-small cell lung cancer (NSCLC) and breast cancer in our knowledge society .

Personnalisé traitement pour le cancer du à petites cellules non poumon (CBNPC) et le cancer dans notre société Want to be de la connaissance .

Literature: -
1. Nabil DEEB,  Personalized therapy for non-small cell lung cancer (NSCLC) and breast cancer in our knowledge society! , Germany  Bonn, PMI Registered Doctors'Association , 53 140 Bonn / GERMANY. 29/09/2010 .

2. The Rest of the literature with the author Dr. Nabil DEEB .

Sincerely Yours fraternally

      Nabil Deeb

Doctor - Physician – Doctor

PMI Medical Association e.V.

Palestine Medico International Medical Society - (PMI)  e.V.

Department of Medical Research

Département de la recherche médicale

P.O. Box 20 10 53

53 140 Bonn - Bad Godesberg / GERMANY

e.mail: doctor.nabil.deeb.pmi.germany @ googlemail.com

or


e.mail: doctor.nabilabdulkadirdeeb@ googlemail.com

5/4/2012

 

" All Rights Reserved To www.paliraq.com "

 

الكلمات الوصفية

اترك تعليقك

التعليقات 3

  • Dr. Nabil AbdulKadir DEEB GERMANY – 53173 Bonn nabildeeb-syndrom, mRNA and APOBEC3 B - Research In the Nature Genetics | Analysis see the following research in U.S. A. more medical resarch about my medical reserchs nabildeeb-syndrome and mRNA / …… • I. • anorectal malformations associated with urologic and neurologic malformations caused by the effects of depleted uranium ( = DU ) on the stateless Palestinian refugee child Zina .- nabildeeb-syndrome . • See ! = 8/26/2012 www.paliraq.com • • anorectal malformations associated with urologic and neurologic malformations caused by the effects of depleted uranium ( = DU ) on the stateless Palestinian refugee child Zina . • nabildeeb-syndrome • Nabil DEEB • Arzt – Physician – Doctor • PMI-Ärzteverein e.V. • Palästinamedico International Ärzteverein – ( P M I ) e.V. • Palestine Medico International Doctors Association ( P.M.I.) registered association • Department of Medical Research • Département de la recherche médicale • P.O. Box 20 10 53 • 53140 Bonn – Bad Godesberg / GERMANY • • e.mail: doctor.nabil.deeb.pmi.germany@googlemail.com • • Dr. Nabil Abdul Kadir DEEB • GERMANY 53137 Bonn • e.mail: doctor.nabil.deeb.pmi.germany@googlemail.com • • • • anorectal malformations associated with urologic and neurologic malformations caused by the effects of depleted uranium ( = DU ) on the stateless Palestinian refugee child Zina . • nabildeeb-syndrome • • Abstract :- • • The 3 years-old stateless Palestinian child Zina has since her birth a deformity of the colon, a major malformation of the anus and a fistula of the common pathology of the bladder and colon with an atrophy of the colon desendens. • The little girl Zina was operated on emergency and Colostomy (naturalis) Colostomy in the abdominal wall for defecation (in a collection bag) on the right colon asendens as a substitute for the anus, so can the little girl stay alive and for later the ascending colon , colon asendens`, to strengthen and further more for specific diagnoses and special operations. The little girl Zina must be re-operated on several occasions in a special pediatric surgery clinic specializing in pediatric surgery for rectal malformations and complications in the U.S., Canada or Europe. These diseases , anorectal malformations associated with urologic and neurologic malformations , of the child Zina are caused by the effects of depleted uranium ( = DU ) on the child Zina and on her mother during the early pregnancy of her mother in the IRAQ - BAGHDAD, because they lived in Baghdad in areas, where contamination depleted uranium ( = DU ) was and is high . • • The little girl, Zina Mohammed Hussein Al - Gazar • the effects of depleted uranium ( = DU) on the child Zinaanorectal malformations associated with urologic and : • neurologic malformations Colostomy (naturalis) Colostomy in the abdominal wall for defecation (in a collection bag) on the right colon asendens . • • the stateless Palestinian refugee child Zina • • Infection • • Colostomy (naturalis) Colostomy in the abdominal wall for defecation (in a collection bag) on the right colon asendens as a substitute for the anus, so can the little girl stay alive the stateless Palestinian refugee child Zina . • • • The little girl, Zina Mohammed Hussein Al - Gazar • the effects of depleted uranium ( = DU) on the child Zinaanorectal malformations associated with urologic and : • neurologic malformations Colostomy (naturalis) Colostomy in the abdominal wall for defecation (in a collection bag) on the right colon asendens • The little girl, Zina Mohammed Hussein Al - Gazar was born at 02. November 2009 in Baghdad - Iraq. She is a child stateless Palestinian refugee, and living at the time of political unrest and expelled from Iraq in the UNHCR - the refugee camp in the desert between Iraq and Syria on Syrian territory under temporary in care and contactor of the UNHCR and waits with her parents and two healthy sisters to live in a country anywhere in the world through the agency, UNHCR – Geneva . • When the intake of these above mentioned refugees is uncertain and often lasts two to five years waiting in UNHCR - refugee camp in the desert near the Iraqi-Syrian border . • The 3-years-old girl suffering from birth under "" Anorectal malformation "" (= congenital malformations of the rectum and the anus) as a result of the developmental disorder of embryo in the early stages of pregnancy of her mother because of the radiation depleting effect of the environment in the home of their mother in Baghdad . • It was a temporary colostomy (colostomy =) at the university hospitals - Baghdad in March 2010 created the child, give the child a temporary chair to give way, which is for her vital moment . • Another treatment for the child in the Palestinian desert in a refugees camp was and still is not possible for many reasons . • The child needs urgent and more vital operational treatment as a pulling operation (posterior sagittal anorectal PSARP = plastic) with a minimally invasive surgery is used . • Such further treatment in a special children's surgery – clinic for example in U.S.A , Canada , in Europe, for example in ,Finland, Norway, Sweden, France or in the Federal Republic of Germany in a department of pediatric surgery . • The three-years-old girl Zina is waiting since her birth to 02 November 2009 with her two little healthy sisters and her parents in the desert between the Iraqi and Syrian deserts in - the refugees UNHCR camp to a reasonable medical surgical treatment in a country . • Without appropriate treatment for the child's life little girl Zina would be destroyed forever because permanent serious infections and cancer degeneration . • In this context, I refer-so called International Humanitarian Law . • In comparison to the treatment of children in the rest of the world as in Europe , Canada or the U. S. A . • • • These diseases , anorectal malformations associated with urologic and neurologic malformations , of the child Zina are caused by the effects of depleted uranium (DU DU) on the child Zina and on her mother during the early pregnancy of her mother in the IRAQ - BAGHDAD, because they lived in Baghdad in areas where the contamination depleted uranium ( = DU ) was and is high. • • The leukemia, birth defects, miscarriages, genetic damage in humans, especially in pregnant women and children, and traumatic injury in the toxic depleted uranium war against the Palestinian people in GAZA Strip and in IRAQ: - • In many regions of the world in which children are exposed to political unrest and wars to military weapons. • In the above-mentioned. Study "," Trends in Childhood Leukemia in Basrah, Iraq, 1993-2007 "," could prove to the American colleagues, increased diseases of children with leukemia at the widespread use of depleted uranium are strong. • Depleted uranium in the senseless, chemo massive nuclear war against the Palestinian people the GAZA Strip and the IRAQ: - • • Uranium projectiles were used in the Palestinian GAZA Strip by the Israeli occupying forces against GAZA - strips. • Among the many Palestinians who were killed just before the war in Gaza, joins the effected either continuously by the effects of depleted uranium ( = DU ) or by a combination of causes increasing numbers of sick and dead, there are mainly children and adolescents. The outbreak of the disease, in the case of DU poisoning can be up to 50 years away, the current numbers are just the beginning. • The effects of DU cover a period of up to several thousands of years, and are therefore never be undone (for literature). • On the whole GAZA territory, waters, air, vegetation and the animals have been severely poisoned. And as for the people, so fast the disease and the deaths at an incredible speed in the air. • Effects of depleted uranium munitions: - • Uranium is one of the elements with the highest specific weight and the highest density. • Health caused by depleted uranium: - • Disease, all living things - not just people - come to the uranium munitions and the Uranium oxide in contact: defense workers in the production of ammunition, soldiers during transport, the camps and when shooting the ammunition, all living in the area of operation and all living things, the food consume from the mission area, because the uranium can also access via the food chain in the body. Uranium oxide of 2.5 micron size, no one can see, smell or taste. When are ingested with food particles of uranium, only 0.2% through the gut into the body, the rest is excreted in the feces. Mainly, uranium oxide is inhaled, enter the lung tissue, and thus into the blood. You are in the body fluids is very difficult to dissolve. They are stored mainly in the skeleton, which serves as a long-term depot. • The "biological" half life "is the time in which half of the absorbed uranium is excreted. It is definitely longer than a year. • Through the bloodstream, the uranium enters the liver and kidneys, where it poisons the cells. The acute risk to health exists in a chemical poisoning by the heavy metal uranium, similar to a cadmium or lead poisoning, only it takes is a much smaller amount of it. With continued steady supply of small quantities of uranium from the bone store the nephrotoxic effects of other environmental toxins we are exposed is amplified. • • The acute heavy metal poisoning by uranium leads to malfunctioning of kidneys and liver, to the lethal loss of function. The damaged liver is unable to protein synthesis and the colloid osmotic pressure is necessary to maintain, shall enter the water out into the abdominal cavity. The injured kidney is unable to excrete the water. • Second Health damage caused by low radiation doses: - • The chronic uranium poisoning leads to AIDS - like immune deficiency or cancer, especially leukemia. Also natural radioactivity caused a number of cancers, because there are no harmless low radiation. Since the uranium is stored in the bones, there is the starting point of the low-level radiation. The tissue that is in-rays is closest to the bone marrow, the organ inaReichweite of the blood cells and immune cells are formed. If this immune and blood forming organs contaminated with radiation, there is a severe form of anemia (aplastic anemia), for cancers such as leukemia or other malignant neoplasms or immune deficiency. Consequences of the immune defect is most severe histories of measles and polio, salmonella and worm infections , herpes and Zoster skin diseases . • When the skin contact with depleted uranium it comes to slow-healing wounds with painless ulcers. Therefore, they are painless because the pain-sensing and conducting sensory and nerve cells have been destroyed. • Finally, is caused by the depleted uranium genetic damage. There is a cluster of miscarriages, stillbirths and birth children unviable. • Uranium poisoning of parents living with children were born following congenital malformations: - • • hydrocephalus with cranial nerve disorder and dementia • phocomelia, a severe malformation of the extremities, such as after thalidomide • • lack of cartilage formation in the lower extremities • malformation of one leg with one hand grasping function • malformation of legs, growing together of the fingers and toes • Cleft lip and cleft palate • abdominal gap • • Spina bifida, cleft of the spinal column. During the second World War was planning in October 1943 by Germany a large-scale radioactive contamination of the war. At this time of year is also developing "special bullets" back. The U.S. intelligence had received from this knowledge, however. • DU shells were of the Allied troops in the Gulf War in 1991 applied for the first time, with devastating effects and consequences. • • Ref. See nabildeeb:- • http://www.springermedizin.at/artikel/18287-neue-therapie-bei-blutkrebs-in-aussicht • I.:- II. Evidence for APOBEC3B mutagenesis in multiple human cancers • Michael B Burns, • Nuri A Temiz • & Reuben S Harris Nature Genetics (2013) doi:10.1038/ng.2701 Published online 14 July 2013 • Abstract • Abstract• • References• • Author information• • Supplementary information Thousands of somatic mutations accrue in most human cancers, and their causes are largely unknown. We recently showed that the DNA cytidine deaminase APOBEC3B accounts for up to half of the mutational load in breast carcinomas expressing this enzyme. Here we address whether APOBEC3B is broadly responsible for mutagenesis in multiple tumor types. We analyzed gene expression data and mutation patterns, distributions and loads for 19 different cancer types, with over 4,800 exomes and 1,000,000 somatic mutations. Notably, APOBEC3B is upregulated, and its preferred target sequence is frequently mutated and clustered in at least six distinct cancers: bladder, cervix, lung (adenocarcinoma and squamous cell carcinoma), head and neck, and breast. Interpreting these findings in the light of previous genetic, cellular and biochemical studies, the most parsimonious conclusion from these global analyses is that APOBEC3B-catalyzed genomic uracil lesions are responsible for a large proportion of both dispersed and clustered mutations in multiple distinct cancers. View full text At a glance Figures First | 1-3 of 4 | Last view all figures left 1. Figure 1 2. Figure 2 3. Figure 3 4. Figure 4 right References • Abstract• • References• • Author information• • Supplementary information 1. Stephens, P. et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37, 590–592 (2005). o CAS o ISI o PubMed o Article 2. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007). o CAS o ADS o ISI o PubMed o Article 3. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228–231 (2010). o CAS o ADS o ISI o PubMed o Article 4. Sjöblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006). o CAS o ADS o ISI o PubMed o Article 5. Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087–17092 (2011). o ADS o PubMed o Article 6. Parsons, D.W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435–439 (2011). o CAS o ADS o ISI o PubMed o Article 7. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011). o CAS o ADS o ISI o PubMed o Article 8. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011). o CAS o ADS o ISI o PubMed o Article 9. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012). o CAS o PubMed o Article 10. Stephens, P.J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012). o CAS o PubMed 11. Makridakis, N.M. & Reichardt, J.K. Translesion DNA polymerases and cancer. Front. Genet. 3, 174 (2012). o CAS o PubMed o Article 12. Roberts, S.A. et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424–435 (2012). o CAS o PubMed o Article 13. Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228–235 (2013). o CAS o PubMed o Article 14. Harris, R.S., Petersen-Mahrt, S.K. & Neuberger, M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247–1253 (2002). o CAS o ISI o PubMed o Article 15. Di Noia, J.M. & Neuberger, M.S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1–22 (2007). o CAS o PubMed o Article 16. Longerich, S., Basu, U., Alt, F. & Storb, U. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol. 18, 164–174 (2006). o CAS o PubMed o Article 17. Conticello, S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9, 229 (2008). o CAS o PubMed o Article 18. LaRue, R.S. et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494–497 (2009). o CAS o PubMed o Article 19. Malim, M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Phil. Trans. R. Soc. Lond. B 364, 675–687 (2009). o CAS o Article 20. Harris, R.S., Hultquist, J.F. & Evans, D.T. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 287, 40875–40883 (2012). o CAS o PubMed o Article 21. Blanc, V. & Davidson, N.O. C-to-U RNA editing: mechanisms leading to genetic diversity. J. Biol. Chem. 278, 1395–1398 (2003). o CAS o ISI o PubMed o Article 22. Bishop, K.N., Holmes, R.K., Sheehy, A.M. & Malim, M.H. APOBEC-mediated editing of viral RNA. Science 305, 645 (2004). o CAS o ISI o PubMed o Article 23. Petit, V. et al. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J. Mol. Biol. 385, 65–78 (2009). o CAS o PubMed o Article 24. Ikeda, T. et al. Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Res. 39, 5538–5554 (2011). o CAS o PubMed o Article 25. Petersen-Mahrt, S.K., Harris, R.S. & Neuberger, M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418, 99–103 (2002). o CAS o ADS o ISI o PubMed o Article 26. Petersen-Mahrt, S.K. & Neuberger, M.S. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J. Biol. Chem. 278, 19583–19586 (2003). o CAS o ISI o PubMed o Article 27. Pham, P., Bransteitter, R., Petruska, J. & Goodman, M.F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424, 103–107 (2003). o CAS o ADS o ISI o PubMed o Article 28. Chelico, L., Pham, P., Calabrese, P. & Goodman, M.F. APOBEC3G DNA deaminase acts processively 3′ 5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 13, 392–399 (2006). o CAS o PubMed o Article 29. Hultquist, J.F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220–11234 (2011). o CAS o ISI o PubMed o Article 30. Robbiani, D.F. & Nussenzweig, M.C. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu. Rev. Pathol. 8, 79–103 (2013). o CAS o PubMed o Article 31. Okazaki, I.M. et al. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197, 1173–1181 (2003). o CAS o ISI o PubMed o Article 32. Yamanaka, S. et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl. Acad. Sci. USA 92, 8483–8487 (1995). o CAS o ADS o PubMed o Article 33. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013). o CAS o ADS o PubMed o Article 34. Jarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285–296 (2002). o CAS o ISI o PubMed o Article 35. Refsland, E.W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010). o CAS o ISI o PubMed o Article 36. Koning, F.A. et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83, 9474–9485 (2009). o CAS o ISI o PubMed o Article 37. Lackey, L. et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301–314 (2012). o CAS o PubMed o Article 38. Kohli, R.M. et al. Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J. Biol. Chem. 285, 40956–40964 (2010). o CAS o PubMed o Article 39. Wang, M., Rada, C. & Neuberger, M.S. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J. Exp. Med. 207, 141–153 (2010). o CAS o PubMed o Article 40. Albin, J.S. & Harris, R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12, e4 (2010). o CAS o PubMed o Article 41. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2013). o CAS o PubMed o Article 42. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013). o CAS o ADS o PubMed o Article 43. Berger, M.F. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502–506 (2012). o CAS o ADS o PubMed 44. Fujino, T., Navaratnam, N. & Scott, J. Human apolipoprotein B RNA editing deaminase gene (APOBEC1). Genomics 47, 266–275 (1998). o CAS o PubMed o Article 45. Muramatsu, M. et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274, 18470–18476 (1999). o CAS o ISI o PubMed o Article 46. Stenglein, M.D., Burns, M.B., Li, M., Lengyel, J. & Harris, R.S. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222–229 (2010). o CAS o ISI o PubMed o Article 47. Sato, Y. et al. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. J. Biol. Chem. 285, 7111–7118 (2010). o CAS o PubMed o Article 48. Rogozin, I.B., Basu, M.K., Jordan, I.K., Pavlov, Y.I. & Koonin, E.V. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4, 1281–1285 (2005). o CAS o PubMed o Article 49. Rada, C., Jarvis, J.M. & Milstein, C. AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization. Proc. Natl. Acad. Sci. USA 99, 7003–7008 (2002). o CAS o ADS o PubMed o Article 50. Land, A.M. et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and non-genotoxic. J. Biol. Chem. 288, 17253–17260 (2013). o CAS o PubMed o Article Download references Author information • Abstract• • References• • Author information• • Supplementary information Affiliations 1. Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA. o Michael B Burns, o Nuri A Temiz & o Reuben S Harris 2. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. o Michael B Burns, o Nuri A Temiz & o Reuben S Harris 3. Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA. o Michael B Burns & o Reuben S Harris 4. Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA. o Michael B Burns & o Reuben S Harris

  • important

    8

    good job doctor the all government medal East DO More Bade for the palestine people because good business for every bade similar UNHCR ....... JAWAD ABO GHAITH America

  • GERMANY Bonn

    32

    ألدكتور نبيل عبدالقادر ديب ألملحم شخصية التشخيص والعلاج لأمراض ألسرطان ألحديثه وألدور ألسلبي لألأمم المتحدة ولمنظمة الصحة العالمية ولألمفوضية في علاج ألأطفال ألفلسطينين المصابين في ألسرطانات وعواقبها ! د. نبيل عبدالقادر ديب ألملحم نحن الأطباء والباحثون في مجال الطب في جميع أنحاء العالم نعمل ونبحث العلوم الطبية مع وسائل التكنولوجيا المتقدمة لتشخيص و لعلاج العديد من الأمراض بما فيها أمراض ألسرطان . للأسف نجد أن العديد من ألأطفال ألفلسطينيين وخاصة من فلسطينيت ألعراق و من قطاع غزه مصابين بأمرا ض السرطان متعددة ألأنواع وبعواقب ألسرطان ألوخيمه بسب ألحروب ألأخيره في منطقة ألشرق ألأوسط وخاصة في ألعراق و قطاع غزه و التي ادت الى سرطانات في ألنسمه و خاصة أطفال ألمنطقه بما فيهم ألأطفال ألفلسطينيين . ولكن بألنسبه للفلسطينين هم أكثر ضحية ألحروب حيث لا يسمح و لا يمكن علاج الأطفال الفلسطينيين المشتتين بصوره صحيحه لأنهم بدون دوله تحميهم و لا ممكن علاجهم في أوربا برفقه أهلهم ألمشتتين ولا أعطائهم فيزا فقط للعلاج و خاصة أوربا ألوسطى بحجة أنهم عديمي ألجنسيه و لن يتم علاجهم بألرغم من هده ألدول ألأوربيه ألوسطى ألتي تتدعي بألديموقراطيه و ألأنسانيه هي سبب مباشر أو غير مباشر بأسباب مرض ألسرطانات عند ألأطفال في مناطق ألحروب في ألشرق ألأوسط . ، اني أشير ألى ما يسمى بألقوانين ألدوليه وما يسمى بحقوق ألأنسان في ألعالم و تأثير ألأزمه ألماليه ألدوليه على ألحروب في ألشرق ألأوسط ز و اني أؤد أن أضيف مقالي ألطبي ألعلمي ليساعد ألقاريء ألعربي عن ألمعرفه ألحديثه لتشخيص و علاج ألسرطان التي هي هي أيضا من تخصصي و مشترك في بحوثها عالميا في جميع ألمستويات وهو ما يلي : شخصية التشخيص والعلاج للسرطان ألحديث في مجتمع المعرفة . ألبروتيوم : ... البروتيوم هو مجموعة من البروتينات التي توجد في النظام البيولوجي في أي وقت معين. ويمكن في خلية واحدة أن يكون a``،``` او أكثر مختلف البروتينات موجودة في كميات مختلفة جدا. في حين أن الجينوم، المعنى المحدد في المعلومات الوراثية DNA للحياة يزال هو نفسه بدون تغير . ألبروتيوم يتغير مرة أخرى و يتغير بأستمرار حسب ألحالة الراهنة لنظام بيولوجي معين. بسبب ألتغيرات في مجموعة ألبروتينات حسب نضام بيولجي معين تكون فائدتنا في بحوثنا الطبيه العلميه المعقده من أجل تشخيص و علاج ألسرطان تقع على أمل البروتيوميات لتحسين عملية البحث عن تغييرات في تكوين البروتين من فرص تشخيص نوعية ألسرطان و كيفية العلاج الطبي للسرطان. المؤشرات الحيوية هي عبارة عن جزيئات من أنماط معينة مميزة التي تشير إلى العمليات البيولوجية المحددة. فإنها يمكن أن توفر لنا معلومات حول ما إذا كان المريض يستجيب للعلاج . الجزيئية مسببات السرطان : الجزيئية مسببات السرطان حيث تتحول الطفرات العشوائية في أي خلية في الجسم تؤدي إلى زيادة نمو الإشارات وإصلاح أنظمة الحماية أو إيقاف تشغيله. فقط عندما يجتمع أكثر من هذه التغيرات الجينية بالسلبيه يتسبب مرض السرطان. .. هناك العديد من التركيبات الممكنة الهائلة بسبب ألتغيرات أو الطفرات ألجينيه التي يمكن أن تؤدي إلى نتيجة مماثلة للسرطنه وأن يكون كل ورم هو فريد من نوعه. بالإضافة إلى ذلك ممكن أن تكون هده أالتغيرات ألجينيه ألسلبيه قد ورثت التكوين الأساسي الوراثية بتغير الجينات للمريض نفسه و تلعب دورا مهم في التسلسل الجيني للمريض. ولذلك نحلل السرطان حسب الجزيئية لعلاج المريض كل على حدة. في علم الطب الشخصي من البيولوجيا الجزيئية يتم الجمع بين وسائل التشخيص والعلاج. حيث يتم تحديد هذه المؤشرات الحيوية . في الأساس وألاكتشافات في البحث عن المؤشرات الحيوية يمكننا في الآونة الأخيرة من خلال استخدام وسائل علميه و تكنولوجيه عالية الإنتاجية إلى حد كبير ما. نجاح التشخيص الطبي و ألعلاج يتوقف على الأهداف الجزيئية في البحث عن مرض محدد المؤشرات الحيوية الجزيئية و التعرف على هذه الاستراتيجية الجزيئات و في المستويات التالية : • الجينوم (البحث عن الأشكال الوراثية، النيوكلوتايد) • في transcriptome (مجموع جميع في مرحلة ما في خلية أو نسيج تنتج كمرسل جزيئات الحمض النووي ) • للبروتيوم (مجموع جميع في مرحلة ما في خلية أو نسيج توليفها البروتينات). الكروموسومات : الكروموسومات تتكون من الحمض النووي و بالإضافة إلى نحو 50 في المئة من البروتينات. هذه البروتينات هي مواد التعبئة والتغليف الحمض النووي والسيطرة على وجه التحديد تفعيل وتعطيل الجينات وأشكالها ووظائفها المحددة . على الرغم من أن هذه الخلايا تحتوي على واحد وتسلسل الحمض النووي نفسه. مثل أغلب الأنظمة الطبيه البيولوجيه ألكيميائيه المعقدة هو أيضا تنظيم نشاط الجينات من قبل التعبئة والتغليف البروتين من الحمض النووي و تعرضة للخطأ. وعلى الرغم من أن معظم الضرر يمكن إصلاحه بنجاح. ولكن يحصل في بعض الأحيان تنظيم الجينات من خلية وتتحول في النهاية عن نطاق السيطرة والخلية إلى خلية سرطانية. مثل هذه التغييرات في الجينوم لا تقل أهمية لتطور السرطان مثل طفرات الحمض النووي المعروفة، على الرغم من عدم تلف تسلسل الحمض النووي نفسه بذلك. وفي مدة مميزة يحدث تعديلات جينية. وعلى النقيض من التعديلات الجينية حيث يتم تغيير تسلسل الحمض النووي. األإنجازات الأساسية للبحوث الجينوم الحديثة، والتقدم التكنولوجي في مجال البيولوجيا الجزيئية والكيمياء الحيوية، وتحسن طرق التشخيص والتكنولوجيات الجديدة يمكن تطوير عقاقير ضد الخلايا السرطانية، وتطوير علاج سرطان مخصصة وشخصية. العامل الحاسم هو اكتشاف \"أخطاء التحويل\" الجزيئية في الخلايا السرطانية التي يمكن الكشف عنها بواسطة إجراءات التشخيص المناسبة وتصحيحها عن طريق الأدوية مع تأثير تستهدف جزيئيا. وقد أكدت الدراسات الدولية الكبيرة لنجاح النهج علاج شخصي في علاج السرطان والاستجابة العلاجية والبقاء على قيد الحياة لمرضى السرطان للمرضى الذين يعانون من المايلوما، سرطان الغدد الليمفاوية، وسرطان الثدي و سرطان البروستاتا و سرطان القولون في السنوات الأخيرة. وقد أدت هذه النجاحات إلى التطبيق الواسع لهذه العلاجات لعدة أنواع من ألسرطان. السرطان ينجم نتيجة التغيرات الجزيئية التي تؤدي الى اضطراب دائم من تنظيم الجينات في ألتسلسل الحمض النووي ألسليم نفسه. على وجه الخصوص، وهذه هي التغييرات في البروتينات خاصة. وحاليا لنا طرق علميه طبيه في البحث ألطبي ألعالمي و فرص جديدة للكشف عن السرطان وتشخيص السرطان و العلاج من مرض السرطان نوعاما. حسب معلوماتنا ألحديثه يمكن تطوير علاجات تستهدف جزيئيا سرطان العديد من مرضى السرطان فرصة للعلاجات أفضل فعالية مع آثار جانبية أقل مقارنة ما هو مع العلاج الكيميائي التقليدي وأفضل البقاء على قيد الحياة. هذه عقاقير مضادة للسرطان الحديثة هي المواد المناعية ( أي الأجسام المضادة ) . استخدام هذه الأدوية وفقا لخصائص بيولوجية معينة من السرطان، وعادة ما يتطلب تشخيص السرطان مكلفة والكثير من الخبرة على جزء من علاج سرطان المتخصصين في التعامل مع هذه الأدوية. وفي الحقيقه كما نجده ألأن في مستشفيات جامعيه خاصه لهدا ألتشخيص و ألعلاج بمساندة أكبر شركات ألعالم للأدويه . ألدكتور نبيل عبدالقادر ديب ألملحم باحث طب علمي أخصائي في ألمانيا من فلسطينيو ألعراق مقيم في ألمانيا يون doctor.nabilabdulkadirdeeb@googlemail.com

شارك برأيك

الاسم
الدولة
التعليق




A- A A+